MANGALAM DRUG & CHEM LTD
MANGALAM · General/Diversified · NSE
₹29
Current Market Price
Fair Value (DCF)
₹112
Margin of Safety
+291.1%
Updated 1d ago
YieldIQ Score
43/100
Piotroski F-Score
7/9
Economic Moat
None
Confidence
30%
ROE
—
Debt/Equity
0.80
WACC
11.1%
Market Cap
₹45 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
9.1%
Return on capital employed
EV / EBITDA
42.5×
Enterprise multiple
Debt / EBITDA
28.5×
Leverage vs earnings
Interest Coverage
1.4×
EBIT covers interest
Current Ratio
1.04×
Short-term liquidity
Asset Turnover
0.86×
Revenue per ₹ of assets
Revenue CAGR (3Y)
-11.0%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹28.72
Bear case
₹69.82
MoS +58.9%
Base case
₹112.32
MoS +74.4%
Bull case
₹191.67
MoS +85.0%
Ratio Trends
MANGALAM · last 4 annual periods
ROE
4.5%
ROCE
13.3%
Operating Margin
—
Debt / Equity
0.65×
PE
122.1×
EV / EBITDA
10.9×
Historical Financials
MANGALAM · Annual, last 4 years· amounts in ₹Cr unless noted
| Metric | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|
| Revenue | ₹447 Cr | ₹366 Cr | ₹365 Cr | ₹315 Cr | -11.0% |
| EBITDA | ₹45.2 Cr | ₹22.1 Cr | ₹14.0 Cr | ₹32.6 Cr | -10.3% |
| EBIT | — | — | — | — | — |
| PAT | ₹19.7 Cr | ₹1.3 Cr | ₹-9.1 Cr | ₹6.7 Cr | -30.1% |
| EPS (diluted) | — | — | — | — | — |
| CFO | ₹25.7 Cr | ₹39.5 Cr | ₹3.9 Cr | ₹42.6 Cr | +18.3% |
| CapEx | ₹-27.7 Cr | ₹-27.9 Cr | ₹-11.8 Cr | ₹-20.2 Cr | — |
| FCF | ₹-2.0 Cr | ₹11.6 Cr | ₹-7.9 Cr | ₹22.4 Cr | — |
| Total Assets | ₹328 Cr | ₹360 Cr | ₹334 Cr | ₹366 Cr | +3.7% |
| Total Debt | ₹87.9 Cr | ₹88.5 Cr | ₹106 Cr | ₹96.2 Cr | +3.1% |
| Shareholders' Equity | ₹151 Cr | ₹152 Cr | ₹136 Cr | ₹149 Cr | -0.4% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
MANGALAM vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| LASA LASA | — | — | Pending | -17.6% | — |
| BIOFILCHEM BIOFILCHEM | — | — | Pending | 3.0% | — |
| VIVIMEDLAB VIVIMEDLAB | — | — | Pending | 90.9% | — |
| VAISHALI VAISHALI | — | — | Pending | 1.3% | — |
| PAR PAR | — | — | Pending | 13.5% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for MANGALAM in the last 10 years.
Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of MANGALAM →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for MANGALAM →
Compare
Head-to-head with peers
Compare MANGALAM side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse MANGALAMNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.